Page 2 - Sanket Koul

Borderline case: Cosmetics from Pakistan breach Indian mkt, raise eyebrows

Drugs regulator says beauty creams from across the border are not registered, and contain excessive, toxic heavy metals

Fortis moves SC against HC forensic audit order in company transactions

Fortis challenges forensic audit order in Supreme Court over alleged asset erosion during Daiichi Sankyo enforcement proceedings

Genpact leases 400K sq ft of office space in Gurugram for around ₹420 cr

The multi-year transaction will see Genpact occupy the entire Kings Canyon tower at ASF Insignia, an integrated 50-acre commercial IT campus in Gurugram

Domestic medtech manufacturers welcome Maha FDA's call for price review

AIMED backing comes after Maharashtra FDA Commissioner Tukaram Mundhe flagged mark-ups of up to 2,841% on medical devices and hospital consumables

Lupin to bet big on biosimilar sales in mid term, ramp capacity expansion

The company plans to soon start the funding process for its oncology spin-off, Kaveri Therapeutics, which houses two specialised oncology programmes

Student housing faces supply gap as private developers shy away

Weak project economics, high land cost, regulatory issues key hurdles

Brics nations push joint disease surveillance, medical product regulation

Grouping eyes more collaboration on treatment TB, NCD and mental health

Kotak Realty Fund to invest over ₹800 crore in 2 Gurugram projects

Kotak Realty Fund invests ₹800 crore in two luxury housing projects by Smartworld Developers in Gurugram, deepening institutional capital flows into premium residential real estate

HPV vaccination drive crosses 8 mn doses as India targets cervical cancer

Seven months after the national campaign was launched, Gujarat, Uttar Pradesh, Madhya Pradesh and Mizoram have achieved 100 per cent vaccination coverage

Godrej Properties sees ₹70 cr impact from Gurugram project settlement

Realty firm says disputes with Orris Infrastructure over Godrej Air have been amicably settled; actions under the settlement agreement are currently being implemented

Delhi's dichotomy: Big infra projects alongside unauthorised sprawl

Delhi's post-liberalisation growth turned it into a services powerhouse, but housing shortages, unplanned urbanisation, pollution and infrastructure gaps continue to test the capital

Centre pushing Delhi land records digitisation for development: D Thara

Delhi needs a virtual database to consolidate land records, while transit-oriented development norms under MPD 2047 aim to simplify development near transport corridors

Indian pharma market grows 10.7% in August despite 3-month volume low

Pharma sales value rose to Rs 23,272 crore in August, driven by new introductions and double-digit growth in key acute and chronic therapies, even as volume growth slowed

W Health Ventures closes second fund at ₹700 cr, eyes company incubation

Healthcare-focused VC fund plans to deploy seed capital exclusively through a company creation model, targeting eight to 10 startups over a four-year investment period

Maha FDA inspects 2,902 drug establishments, acts against 880 licensees

Maharashtra FDA conducted 104 search and seizure operations between June and August, seizing illegal drugs and cosmetics worth Rs 11.41 crore and registering 20 FIRs

Innovative ecosystem will make India attractive: Judith Love & Amitabh Dube

Novartis doubles down on innovation in India, eyeing R&D, clinical trials and a stronger regulatory ecosystem while moving away from traditional generics

Regulatory data protection will lift India's appeal: Novartis' Judith Love

On what will make India an attractive investment destination, Love said: ''I think the number one for us to make India attractive is to create an innovative ecosystem.''

IIL says NSQ Abhayrab vials were not manufactured by its division

Indian Immunologicals said Abhayrab anti-rabies vaccine vials declared NSQ and misbranded by a government laboratory were not manufactured by its human health division

Roche gets Phase 3 trial waiver for higher dose of multiple sclerosis drug

CDSCO expert panel grants waiver for 920 mg Ocrelizumab, subject to Roche conducting a Phase 4 clinical trial in the Indian population for proposed indications

Refurbished medical device import policy remains under discussion

India's proposed rules for refurbished medical device imports remain unresolved nearly a year after a government panel was formed, amid safety concerns and demand from smaller hospitals